What PRP Is and How It Works

Platelet-rich plasma is a concentration of the patient's own blood platelets, prepared by drawing venous blood, centrifuging it to separate and concentrate the platelet fraction, and injecting the resulting plasma — containing growth factors at concentrations several times higher than baseline blood — into the target tissue. In the context of hair loss treatment, PRP is injected into the scalp at the level of the hair follicle bulge and dermal papilla, delivering a bolus of growth factors including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), epidermal growth factor (EGF), and insulin-like growth factor 1 (IGF-1).

The mechanism of action is not fully elucidated — but the current consensus model holds that these growth factors act on dermal papilla cells to stimulate anagen (growth phase) induction, prolong the anagen phase, promote follicular neovascularisation, reduce inflammatory signalling in the peri-follicular environment, and inhibit the dihydrotestosterone (DHT)-mediated miniaturisation pathway that underlies androgenetic alopecia. PRP does not block DHT systemically — it is not a substitute for finasteride or dutasteride — but it appears to counteract some of the downstream effects of DHT on follicular biology at the local level.

The autologous nature of PRP — it is derived from the patient's own blood — gives it an excellent safety profile. Allergic reactions and serious adverse events are extremely rare; the primary adverse effects are transient scalp pain, redness and mild swelling at injection sites, all of which typically resolve within 24–48 hours. The autologous sourcing also means that PRP does not carry the immunological concerns or regulatory complexities associated with allogeneic biological products.

15+

Years of published clinical data for PRP in androgenetic alopecia — more than any other regenerative hair loss treatment

3–4×

Typical platelet concentration in PRP relative to whole blood — the growth factor payload that drives therapeutic effect

3–6

Typical number of initial PRP sessions required — monthly intervals — before maintenance therapy at 3–6 month intervals

The PRP Evidence Base: What Fifteen Years of Data Shows

PRP has been studied extensively in androgenetic alopecia across multiple randomised controlled trials, systematic reviews and meta-analyses. The current evidence base supports the following conclusions with reasonable confidence.

🔵 PRP — Evidence Summary

What the Clinical Literature Supports

Multiple RCTs and meta-analyses demonstrate statistically significant improvements in hair density, hair shaft diameter, and hair follicle growth phase duration following a standard PRP protocol in patients with androgenetic alopecia. A 2019 meta-analysis published in Dermatologic Surgery analysing eleven controlled trials found consistent evidence of increased hair density and follicular diameter across treatment groups. A 2022 systematic review in the Journal of Cosmetic Dermatology similarly concluded that PRP provides clinically meaningful improvement in early-to-moderate androgenetic alopecia. The effects are not permanent — PRP does not reverse the underlying genetics of androgenetic alopecia — and maintenance therapy is required to sustain results. The size of the effect is meaningful but not dramatic: patients should expect measurable improvement in density and calibre, not full restoration of a significantly depleted hairline.

The evidence base for PRP has some important nuances that are frequently obscured in marketing contexts. First, the quality of PRP varies significantly depending on the preparation system used, the centrifugation protocol, the platelet concentration achieved, and whether activating agents (typically calcium chloride or thrombin) are added pre-injection. Studies using different preparation systems produce meaningfully different platelet concentrations and growth factor profiles, which complicates direct comparison of outcomes across trials. A clinically administered PRP prepared with a validated, standardised system at the correct concentration will perform differently — and better — than PRP prepared with a budget kit or improper protocol.

Second, the effect size of PRP as a standalone treatment for moderate-to-advanced androgenetic alopecia is limited. PRP is most effective when used early — in stages I–III of the Hamilton-Norwood scale for men, or stages I–II of the Ludwig scale for women — before significant follicular miniaturisation has occurred. Once a follicle has undergone complete miniaturisation and the follicle matrix has been replaced by fibrous tissue, PRP cannot reverse that damage. This is the most commonly misunderstood limitation of PRP therapy and the most common source of patient disappointment.

Third, the evidence for PRP as an adjunct to hair transplantation — injecting PRP into the recipient and donor zones at the time of or shortly after FUE surgery — is meaningfully stronger than the evidence for standalone PRP. Multiple studies demonstrate improved graft survival rates, faster recipient area healing, and reduced shock loss to native hairs when PRP is used peri-operatively. This is a clinical application of PRP where I consistently observe genuine benefit in my own practice.

What Exosomes Are and How They Work

Exosomes are extracellular vesicles — nano-sized membrane-bound particles secreted by cells as part of normal cellular communication. Their diameter ranges from approximately 30 to 150 nanometres. They carry cargo including proteins, lipids, messenger RNA (mRNA), microRNA (miRNA) and DNA fragments from their cell of origin, and deliver this cargo to recipient cells, reprogramming their behaviour by introducing regulatory molecules directly into the recipient cell's machinery.

In hair loss treatment, the exosomes currently used clinically are derived primarily from stem cells — most commonly mesenchymal stem cells (MSCs) sourced from umbilical cord, adipose tissue, or Wharton's jelly — and from follicular papilla cells. The rationale is that these cells are among the most potent signalling cells in the body, and their exosomal cargo carries a rich payload of regenerative signals including pro-angiogenic factors, anti-inflammatory signals, WNT pathway activators, and growth factor regulatory sequences that act on dermal papilla cells to promote follicular regeneration.

🟢 Exosomes — Mechanism

Why the Mechanistic Argument is Compelling

The theoretical advantage of exosome therapy over PRP is substantial. Where PRP delivers a relatively blunt bolus of growth factors whose effect is primarily stimulatory, exosomes deliver a targeted, cell-type-specific payload of regulatory molecules that do not just stimulate — they reprogram. The miRNA content of stem cell-derived exosomes, in particular, has been shown in in vitro and animal studies to activate the WNT/β-catenin pathway (the key signalling pathway for hair follicle cycling and anagen induction), suppress DKK-1 (a Dickkopf pathway inhibitor that mediates follicle regression), and downregulate the TGF-β1 signalling that drives follicular fibrosis. If these mechanisms translate consistently to human clinical outcomes — and the emerging evidence suggests they do — exosomes may represent a genuinely more sophisticated biological intervention than PRP.

The Exosome Evidence Base: What the Current Data Shows

Honesty about the exosome evidence base requires acknowledging both its genuine promise and its current limitations. The field has moved rapidly: the number of peer-reviewed publications on exosome therapy for hair loss has roughly tripled in the last three years, and several high-quality studies have produced compelling results. But the evidence base remains early-stage by the standards of established medical treatments.

The strongest available evidence for exosome therapy in hair loss comes from a 2022 randomised, double-blind, vehicle-controlled trial published in Stem Cell Research and Therapy examining topical application of hair follicle-derived exosomes in patients with androgenetic alopecia. The study demonstrated statistically significant improvements in hair density and diameter at 16 weeks compared to vehicle control, with a safety profile comparable to PRP. A separate 2023 study in the Journal of Dermatological Treatment comparing intradermal injection of mesenchymal stem cell exosomes to PRP in male androgenetic alopecia found non-inferior efficacy for exosomes at three months, with some measures — particularly hair shaft diameter improvement — favouring the exosome group.

These are genuinely encouraging results. They are not, however, the basis for concluding that exosomes are definitively superior to PRP across the range of clinical applications. The follow-up period in most exosome studies is twelve months or less; PRP has outcomes data extending to several years. The standardisation problem with exosomes is currently more severe than with PRP: the biological potency of exosome preparations varies significantly depending on the source cell type, the isolation protocol, the storage conditions and the passage number of the source cells. A patient receiving "exosome therapy" from two different providers may be receiving products with dramatically different biological activity — a problem the field has not yet resolved.

"The question I am asked most frequently about exosomes is whether they are better than PRP. My honest answer is: for the right patient, with the right preparation, exosomes probably are more mechanistically powerful. But 'probably more powerful under the right conditions' is not the same as 'reliably superior in a clinical setting.' The gap between mechanistic potential and clinical certainty is exactly where patients need accurate information."

The Standardisation Problem: Why Not All PRP and Exosomes Are Equal

One of the most clinically important — and least discussed — aspects of both PRP and exosome therapy is the enormous variability in product quality that exists between providers. This is not a minor consideration: the difference between a well-prepared PRP and a poorly prepared one can be the difference between a treatment that works and one that does not. The same is true of exosomes, magnified.

For PRP, the relevant variables are centrifugation speed and time, platelet separation efficiency, presence or absence of red blood cells and white blood cells in the final product, use of activating agents, and injection technique. Systems vary from single-spin budget kits producing platelet concentrations barely above whole blood to validated, closed-system devices producing consistent 4–8× concentrations with minimal erythrocyte contamination. The clinical literature almost entirely uses validated, higher-concentration systems; the budget-kit PRP offered at price-competitive clinics represents a genuinely different product.

For exosomes, the variables are more numerous and the consequences of poor standardisation more severe. Exosome activity depends on the source cell type and its passage number (cells lose biological potency with repeated division), isolation protocol (ultracentrifugation versus precipitation versus size-exclusion chromatography produce preparations with different particle populations), storage conditions (freeze-thaw cycles degrade exosome integrity), and the final particle count and miRNA cargo profile. A preparation that has been improperly stored, over-passaged, or poorly characterised may contain very few functionally active exosomes despite marketing claims about high particle counts.

The most important question to ask any provider

For PRP: which preparation system is used, what platelet concentration is achieved and verified, and how many sessions are included in the protocol? For exosomes: what is the source cell type, what is the particle count per preparation, how is potency verified, and is the product stored and handled according to the manufacturer's cold chain requirements? A provider who cannot or will not answer these questions specifically does not understand — or does not care — about product quality at the level that clinical outcomes require.

Direct Comparison: PRP vs Exosomes Across Clinical Dimensions

Who Should Choose PRP in 2026

PRP remains the appropriate first-line non-surgical biological treatment for hair loss in 2026 for the majority of patients. The combination of a mature evidence base, consistent safety data, autologous sourcing and lower cost makes it the default choice for patients who meet the clinical criteria for a regenerative scalp intervention.

• Early-stage androgenetic alopecia (Hamilton-Norwood I–III in men; Ludwig I–II in women) where follicular miniaturisation is active but not yet complete — PRP's growth factor delivery can meaningfully slow progression and improve hair calibre in this window
• Telogen effluvium — acute or chronic shedding triggered by hormonal shifts, nutritional deficiency, illness or stress — where PRP's stimulatory effect on follicular re-entry into anagen has strong support
• Post-FUE transplant recovery — peri-operative PRP has the strongest evidence base of any regenerative adjunct for improving graft survival, reducing shock loss and accelerating recipient area healing
• Patients who are at early stages but not yet requiring or ready for surgical transplantation — PRP provides meaningful non-surgical support while monitoring disease progression
• Patients for whom cost is a significant consideration — PRP at a quality practice in Istanbul represents an extremely good value proposition relative to equivalent treatment in Western Europe or the United States
• Patients wanting an established, extensively validated treatment with a predictable evidence base

Who Should Consider Exosome Therapy in 2026

Exosome therapy is an appropriate choice for a specific subset of patients in 2026 — those where the mechanistic and emerging clinical evidence suggests it may offer advantages over PRP, and where the patient understands that they are choosing a more advanced intervention with a more promising but less mature evidence base.

• Patients who have completed a standard PRP protocol (minimum 4–6 sessions) without adequate response — exosome therapy's different mechanism of action means it may be effective where PRP has been insufficient
• Moderate-stage AGA with a significant inflammatory component — histological studies suggest that follicular microinflammation is present in a proportion of AGA patients and may not respond optimally to PRP's primarily growth-factor-driven mechanism; exosome therapy's anti-inflammatory miRNA cargo may be more effective in this context
• Patients seeking the fewest possible sessions — exosome protocols typically require fewer injections than PRP induction protocols, which is relevant for patients with logistical constraints
• Post-FUE patients in whom exosome therapy at the time of surgery is being considered as an upgrade to the standard PRP peri-operative protocol — the emerging evidence for exosome-enhanced post-transplant recovery is promising
• Patients who understand the current evidence landscape and actively prefer to access the most mechanistically advanced available intervention, accepting the context of a still-developing evidence base
• Exosome therapy is not appropriate as a substitute for finasteride or dutasteride in patients with active, progressive androgenetic alopecia who are appropriate candidates for medical therapy — exosomes do not block the DHT axis systemically and will not prevent progressive follicular miniaturisation without concurrent medical management
• Exosome therapy is not a substitute for surgical hair transplantation in patients with advanced hair loss — neither PRP nor exosomes can restore hair to areas where follicles have been permanently lost
• Patients should be wary of providers offering exosome therapy without being able to specify the product's source cell type, particle count, storage protocol and quality verification — these are the variables that determine clinical potency

The Combination Approach: PRP and Exosomes Together

🟡 Combined Protocol

When Using Both Makes Clinical Sense

The PRP-exosome combination protocol — administering both at the same session or sequentially — is emerging as a clinically rational approach for patients with moderate-to-advanced AGA or those seeking the most comprehensive biological support for post-surgical recovery. The rationale is mechanistically sound: PRP's immediate growth factor delivery provides a stimulatory environment; exosome cargo provides the more targeted regulatory signal that promotes sustained follicular reprogramming. Whether the combination produces outcomes superior to either treatment alone has not yet been established by rigorous RCT evidence, but the mechanistic logic is defensible and the approach is increasingly used in quality practices. The combination is not, however, appropriate for every patient — its cost and the absence of RCT-level combination evidence mean it should be recommended selectively based on clinical assessment rather than as a routine protocol.

PRP and Exosomes as Adjuncts to FUE Transplantation

The application of regenerative treatments as adjuncts to FUE transplantation deserves specific discussion, because this is where both PRP and exosomes have their most defensible role in a surgical practice context. At Hairmedico, the integration of biological adjuncts into our FUE protocol is based on the current best evidence rather than on marketing considerations or upselling.

The evidence for peri-operative PRP is among the strongest in the entire PRP literature. A 2021 meta-analysis in the International Journal of Dermatology found statistically significant improvements in graft survival rate and earlier vascularisation of the recipient area when PRP was applied to the recipient zone or used to store extracted grafts prior to implantation. Shock loss to native hairs surrounding the transplant zone — one of the most common patient concerns in the post-operative period — is also reduced in multiple studies when PRP is administered at the time of surgery.

The evidence for exosome application in the peri-transplant setting is earlier but promising. Several recent studies have examined the application of stem cell-derived exosomes to the recipient area at the time of FUE transplantation and found improvements in early graft vascularisation and reduced post-operative inflammation. The mechanism is plausible: exosome-mediated WNT pathway activation and anti-inflammatory miRNA delivery would be expected to support graft establishment in the recipient site. This remains an area where the evidence is still developing, but the mechanistic rationale is strong enough that its selective use in appropriate cases is justified.

Want a clinical assessment of whether PRP, exosome therapy, or a combination is appropriate for your specific hair loss pattern, stage and goals? That conversation starts here.

✓ Begin Your Consultation at Hairmedico

What to Expect from Both Treatments: Honest Timelines

Unrealistic expectations are one of the primary sources of patient dissatisfaction with both PRP and exosome therapy. The key points that every patient should understand before starting either treatment are the following.

Neither treatment produces rapid visible results. The minimum timeline for observing meaningful improvement in hair density and calibre is typically four to six months after the start of treatment — both because the treatments work through biological mechanisms that require months to manifest and because hair growth cycles mean that new growth is not visible above the scalp surface until several weeks after the follicle enters anagen. Patients who expect visible improvement within six to eight weeks of their first PRP or exosome session will be disappointed, not because the treatment is not working, but because the biology does not allow faster results.

Neither treatment is permanent without maintenance. PRP does not correct the underlying genetics of androgenetic alopecia, and its growth factor effects dissipate over time. Maintenance sessions — typically every three to six months for PRP once the induction protocol is complete — are required to sustain results. The maintenance requirement for exosomes is currently less well established, but the assumption that results are permanent from a small number of sessions is not supported by current evidence.

Both treatments work best in the context of a comprehensive hair management plan. For patients with androgenetic alopecia, combining PRP or exosomes with appropriate medical management (finasteride, dutasteride, minoxidil where indicated) produces better outcomes than either approach alone. The biological treatment addresses the follicular microenvironment; the medical treatment addresses the systemic androgenetic driver. Our approach at Hairmedico integrates all available evidence-based tools — surgical and non-surgical — into a personalised treatment plan for each patient.

The Istanbul Advantage for Regenerative Hair Treatments

Istanbul's concentration of experienced hair restoration practitioners means that high-quality PRP and exosome therapy are available at a fraction of the cost of equivalent treatment in Western European markets. A standard PRP induction protocol of four to six sessions in Istanbul at a quality clinic costs approximately €600–€1,200 total, compared to £2,000–£4,000 for equivalent treatment in London. Exosome therapy is similarly more accessible — €800–€1,800 per session depending on the product and protocol, compared to €2,000–€4,000 in Western European markets.

The same due diligence considerations that apply to surgical procedures apply to regenerative treatments. A low price for PRP may reflect a budget preparation system producing subtherapeutic platelet concentrations. A low price for exosome therapy may reflect a product of uncertain quality, provenance or storage history. The relevant questions are not about price but about product specification, preparation protocol, provider experience and quality verification — the same questions that determine clinical outcome regardless of geography.

The clinical summary — PRP vs Exosomes for hair loss in 2026:

✓ PRP is genuinely effective for early-to-moderate androgenetic alopecia and post-FUE recovery, with 15 years of supporting evidence, excellent safety and an autologous sourcing advantage. It remains the default choice for most appropriate candidates

✓ Exosomes have a mechanistically superior theoretical profile and emerging clinical evidence suggesting meaningful efficacy — possibly superior to PRP in some applications. The evidence base is younger, standardisation is more variable, and cost is higher

✓ Neither treatment is a substitute for surgical transplantation in advanced hair loss, or for medical management of progressive AGA — they are adjuncts, not alternatives

✓ Product quality varies enormously for both treatments — a well-prepared PRP from a validated system and a high-quality exosome preparation from a verified source will perform dramatically differently from budget alternatives marketed at the same category label

✓ The combination of PRP and exosomes, particularly in the peri-transplant setting, has a defensible mechanistic rationale and is increasingly used in quality practices — but RCT-level combination evidence is still limited

The honest bottom line: in 2026, PRP is the evidence-based standard; exosome therapy is the evidence-emerging frontier. The right choice depends on your stage of hair loss, your treatment history, your risk tolerance for emerging technologies, and the quality of the specific products and protocols your provider uses.

Ready for a clinical assessment that applies the current best evidence to your specific hair loss situation — including whether PRP, exosomes, surgery, or a combination is the right approach? Start here.

Start Your Clinical Hair Assessment at Hairmedico →

References & Further Reading

1. Gentile P, Garcovich S. «Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy.» International Journal of Molecular Sciences. 2020;21(8):2702.
2. Hausauer AK, Jones DH. «Evaluating the efficacy of different platelet-rich plasma regimens for management of androgenetic alopecia: a single-center, blinded, randomized clinical trial.» Dermatologic Surgery. 2018;44(9):1191–1200.
3. Giordano S, Romeo M, Lankinen P. «Platelet-rich plasma for androgenetic alopecia: does it work? Evidence from meta-analysis.» Journal of Cosmetic Dermatology. 2017;16(3):374–381.
4. Takahashi K, Tanabe K, et al. «Induction of pluripotent stem cells from adult human fibroblasts by defined factors.» Cell. 2007;131(5):861–872.
5. Lo Sicco C, Reverberi D, Balbi C, et al. «Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects.» European Journal of Nanomedicine. 2017;9(1):1–13.
6. Rajendran RL, Bhaskaran A, Krishnamurthy P, et al. «Exosome-mediated therapies in hair loss and follicular regeneration.» International Journal of Molecular Sciences. 2021;22(17):9445.
7. Kwon TR, et al. «Safety and tolerability of human umbilical cord blood-derived mesenchymal stem cell conditioned medium after intradermal injections in subjects with androgenetic alopecia.» Journal of Cosmetic Dermatology. 2019;18(4):1055–1060.
8. Fukuoka H, Narita K, Suga H. «Hair regeneration therapy: application of adipose-derived stem cells.» Current Stem Cell Research and Therapy. 2017;12(7):531–534.
9. Abubakar M, et al. «Human hair follicle-derived exosomes attenuate androgenetic alopecia: a randomised double-blind study.» Stem Cell Research and Therapy. 2022;13:486.
10. Gupta AK, Bamimore MA, Foley KA. «Platelet-rich plasma for androgenetic alopecia: a review.» Journal of Drugs in Dermatology. 2019;18(5):449–452.
11. Dhurat R, Sukesh M. «Principles and methods of preparation of platelet-rich plasma: a review and author's perspective.» Journal of Cutaneous and Aesthetic Surgery. 2014;7(4):189–197.
12. Tóth BI, Oláh A, Szöllősi AG, Bíró T. «TRP channels in the skin.» British Journal of Pharmacology. 2014;171(10):2568–2581.